Skip to main content
Signal8

Stemtech Corp (STEK) Form 10-Q — Nov 13, 2026

$STEKForm 10-QFiled Nov 13, 2026, 3:59 PM ET0001683168-26-008696Original filing

Stemtech's 10-Q for the quarter ended September 30, 2026 carries going-concern language, with an accumulated deficit of $36.8 million, a working capital deficit of roughly $10.7 million, and just $255,555 in cash on hand. Nine-month net sales fell to $1.37 million from $2.42 million a year earlier, driven by distributor losses after product shortages in early 2026. Q3 revenue was $282,484 versus $852,300 in the prior-year quarter, though the quarterly net loss narrowed to $478,575 from $812,541 on cost cuts.

Key figures

Eps
-0.00 (basic and diluted, nine months FY2026)
Revenue
1374753
Total Debt
4544413
Revenue Yoy
-43.2% (nine months: $1,374,753 vs $2,418,271)
Cash Position
255555
Shares Outstanding
2997032856
Current assets
558275
Leviston funded
1561660
Net loss q3 2025
812541
Net loss q3 2026
478575
Net sales q3 2025
852300
Net sales q3 2026
282484
Accumulated deficit
36809750
Current liabilities
11221410
Gross margin q3 2025
80.1%
Gross margin q3 2026
75.6%
Working capital deficit
10663135
Channel partners advance
102000
Interest expense q3 2025
508699
Interest expense q3 2026
109526
Leviston facility capacity
7000000
Operating cash use 9m 2026
777119
Convertible debt converted shares 9m 2026
2293909287

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.